SEC Company Response from Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — Feb 8, 2017
Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: Feb. 8, 2017 · CIK: 0001659617 · Accession: 0001144204-17-006734
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214898
Letter
Re: Moleculin Biotech, Inc.
February 8,
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Registration Statement on Form S-1
Registration No. 333-214898
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:30 P.M. (Eastern Time) on February 8, 2017, or as soon thereafter as possible on such date.
Very truly yours,
Moleculin Biotech, Inc.
Show Raw Text
CORRESP
1
filename1.htm
February 8,
2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Re: Moleculin Biotech, Inc.
Registration
Statement on Form S-1
Registration
No. 333-214898
Ladies and Gentlemen:
Pursuant to Rule 461
of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby
respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will
be declared effective at 5:30 P.M. (Eastern Time) on February 8, 2017, or as soon thereafter as possible on such date.
Very truly yours,
Moleculin Biotech, Inc.
By:
/s/ Jonathan Foster
Name: Jonathan Foster
Title: Chief Financial Officer